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Abstract: Achieving ambitious targets to address the global tuberculosis (TB) epi-
demic requires consideration of the impact of competing interventions for improved
identification of patients with TB. Cost-effectiveness analysis (CEA) and benefit-
cost analysis (BCA) are two approaches to economic evaluation that assess the costs
and effects of competing alternatives. However, the differing theoretical basis and
methodological approach to CEA and BCA is likely to result in alternative analyt-
ical outputs and potentially different policy interpretations. A BCA was conducted
by converting an existing CEA on various combinations of TB control interventions
in South Africa using a benefits transfer approach to estimate the value of statistical
life (VSL) and value of statistical life year (VSLY). All combinations of interven-
tions reduced untreated active disease compared to current TB control, reducing
deaths by between 5,000 and 75,000 and resulting in net benefits of Int$3.2–Int$137
billion (ZAR18.1 billion to ZAR764 billion) over a 20-year period. This analysis
contributes to development and application of BCA methods for health interven-
tions and demonstrates that further investment in TB control in South Africa is
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expected to yield significant benefits. Further work is required to guide the appro-
priate analytical approach, interpretation and policy recommendations in the South
African policy perspective and context.
Keywords: tuberculosis; South Africa; reference case; cost effectiveness analysis;
benefit-cost analysis.
JEL classifications: I18.
1 Introduction
The aim of this case study is to assess the expected impact of investing in various
tuberculosis (TB) control interventions in the South African context using a benefit-
cost analysis (BCA) approach. The analysis tests preliminary recommendations for
conducting BCA in the global health and development context and converts outputs
of a cost-effectiveness analysis (CEA) (Bozzani et al., 2018, 2019).1 This approach
will enable the comparison of CEA and BCA analyses of the same interventions in
the same context and will provide estimates of net benefits of increased investment
in TB control interventions to assist South Africa’s policy response to management
of TB.
2 Policy context
Tuberculosis remains a significant policy priority globally. In 2016, 1.7 million
people died as a result of TB, including 0.4 million deaths among people with
human immunodeficiency virus (HIV). Since 1990, globally there has been a 47%
decline in the TB mortality rate and HIV-related TB deaths have declined by 32%
since 2005. TB is the leading cause of death in South Africa with a mortality rate
of 181 per 100,000 in HIV+ patients and 41 per 100,000 in patients without HIV
(WHO, 2017). In 2014, the South African TB Think Tank was established to advise
the National TB Programme on treatment and prevention policy and programmatic
implementation to achieve the strategic targets for TB (White et al., 2018).
South Africa’s National Strategic Plan for HIV, TB and Sexually Transmitted
Infections 2017–2022 (National Strategic Plan, 2017) outlines the road map for
a comprehensive and integrated infectious disease approach and is aligned to the
1 For more information on this project, see the other articles in this issue and https://sites.sph.harvard.e
du/bcaguidelines/.
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Figure 1 Simplified CEA and BCA frameworks applied in analysis.
global TB response WHO (2015a; 2015b). The National Strategic Plan aims to
reduce national TB incidence from 450,000 to less than 315,000 per year by 2022,
including diagnosis of 90% of people with TB, treating 100% of those diagnosed
and achieving successful treatment for 90% of patients with drug-susceptible TB.
Aiming to reduce morbidity and mortality by providing treatment, care and adher-
ence support for all, the National Strategic Plan increases the need for screening and
testing programmes to appropriately identify patients in order to initiate treatment.
3 Approach to the case study
A CEA assessing the TB control interventions (Bozzani et al., 2018, 2019) was
developed by combining impact estimates generated using the TIME (TB Impact
Model Estimates) epidemiological transmission model. Cost estimates from the lit-
erature and micro-costing of TB control at sites across South Africa were synthe-
sized to estimate the cost-effectiveness of competing interventions.
The TIME model was developed by the London School of Hygiene and Trop-
ical Medicine in collaboration with Avenir Health as a user-friendly tool to pre-
dict the impact of interventions along the TB transmission, diagnosis and treatment
pathways in high-burden settings (Menzies et al., 2016). The CEA that this case
study is based on assessed specific interventions related to screening and diagnosis,
and utilized the TIME model to estimate likely outcomes.
In completing this case study, a BCA methodological framework was applied
to the original CEA analysis (Figure 1), and no additional primary analysis or data
collection was conducted.
In addition to applying the methodological specifications developed for BCA
in global health and development, the case study attempts to apply the recommen-
dations of two linked initiatives: the IDSI Reference Case (Wilkinson et al., 2016),
which provides general guidance for economic evaluation as well as guidance for
CEA, and guidance from the Global Health Cost Consortium Project (Vassall et al.,
2017) on health intervention and services costing.
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Figure 2 Intervention scenarios.
4 Policy options
The National Strategic Plan for TB in South Africa requires a substantial and
rapid scale-up of approaches to identify patients with TB and effectively initi-
ate them on the right treatment. There are a range of policy options that can be
applied individually or in combination to improve TB patient identification, and by
comparing the expected costs and benefits associated with each option, the opti-
mal combination can be identified. The analysis compares ten mutually exclusive
interventions (status quo plus six unique interventions and three intervention com-
binations) for improving TB control as shown in Figures 2 and 3 below. The poten-
tial interventions in Figure 2 were identified in discussion with policy makers and
represent the realistic and immediate policy options.
The current measure to identify patients to initiate the TB diagnostic pathway
include (in order of resource requirements and effectiveness of patient identifi-
cation): (1) passive screening, which relies on patients actively seeking care, (2)
cough triage, which includes a simple question to patients about history of cough-
ing symptoms, and (3) a structured questionnaire with specific questions related to
patient symptoms and clinical history developed by the World Health Organization
(WHO symptoms screening tool).
Under the status quo (Intervention 1), a symptoms screen is conducted in
40% of HIV+ patients using the WHO symptoms screening tool (with no spe-
cific screen intervention for the remainder) and staff at Primary Health Clinics
(PHC) passively screen all patients for TB. Coverage of the rapid diagnostic test
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Figure 3 Intervention scenarios within the TIME model, modified from Menzies N, 2016.
GeneXpert MTB/RIF (Xpert) is currently at 80%, and follow-up of Xpert negative
results is 14%2.
The available options to scale up TB control involve six potential interventions,
each of which have associated costs and expected benefits. The options include
increasing Xpert coverage of identified patients to 100% (Intervention 2); increas-
ing microscopy follow-up of those who have a negative Xpert result to 90% (Inter-
vention 3); and in 100% HIV+ PHC patients and 90% of all PHC patients (regard-
less of HIV status), triaging for cough assessment (Interventions 5 and 6, respec-
tively) or performing WHO symptoms screening (Interventions 7 and 8, respec-
tively). In addition, a further three combinations were assessed that consisted of the
Xpert interventions (100% Xpert coverage and 90% follow-up of negative results),
(Intervention 4); the Xpert interventions combined with cough triage in 90% of
2 Xpert will detect 98% of smear positive, culture positive Mycobacterium Tuberculosis Complex
(MTBC), but will only detect 60%–70% of smear negative, culture positive MTBC; therefore, follow-up
of negative Xpert results was identified as a potential intervention.
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all PHC patients (Intervention 9); and Xpert interventions combined with WHO
symptoms screening in 90% of all PHC patients (Intervention 10).
The impact of the intervention strategies was estimated utilizing the TIME
model, with costs and effects modelled at specific stages in the causal pathway
of TB as shown in Figure 3.
5 Perspective
This analysis adopts a societal perspective in the South African country context.
The primary benefits of the interventions are to individuals in terms of mortality
and morbidity risk reduction associated with improved detection and avoidance of
TB. The costs of providing TB care are funded by government through general
taxation as TB care is provided free of charge to patients at the point of use in
the South African public healthcare system where TB is predominantly provided
(Menzies et al., 2016). This approach aligns with the CEA that adopted a health
systems perspective for costs.
Direct costs of accessing care incurred by third parties (such as carers assist-
ing patients to access health services) are relatively small compared to government
expenditure on TB and are included in sensitivity analysis.
Although accessing treatment for TB can require a significant time burden for
individuals, the analysis does not additionally incorporate impacts associated with
income loss as patients in South Africa suffer relatively low levels of income loss
from TB due to the context of high unemployment rates. A costing analysis involv-
ing TB patients in South Africa found that 69% of those who initiated TB treat-
ment reported no income, and a further 5% accessed government cash transfers as
their main source of income (receipt of which would not be impacted by disease)
(Foster et al., 2015).
6 Baseline Conditions
The baseline comparators are detailed in Figure 2 and consist of Xpert coverage
for 80% of cases, limited follow-up (14%) of those that receive negative Xpert
result, WHO symptoms screening for less than half of patients with HIV, and pas-
sive screening of patients in PHCs. An important aspect of this analysis is that it is
not assessing whether or not to introduce a new individual technology, but assess-
ing the costs and benefits of investing additional resources in order to achieve tar-
get levels of TB patient identification. Therefore, the current baseline comparator is
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the existing screening algorithm, with associated levels of staffing, equipment and
technologies at South African health facilities.
As the interventions represent scaling up of existing interventions, we do not
predict that there would be major societal shifts or structural changes to the econ-
omy as a result of implementing the interventions, beyond of course the potential
significant mortality and morbidity benefits of improved management of TB.
The IDSI Reference Case recommends that, while current practice should be
used in base case analysis, additional analysis should be conducted using best sup-
portive, non-interventional care as a comparator where appropriate to the decision
problem. This case study does not incorporate a non-interventional comparator as
the current policy decision that this analysis seeks to answer is restricted to uti-
lizing existing diagnostic technologies and processes available in South Africa. In
addition, applying a non-interventional (“do-nothing”) comparator for diagnostic
interventions would require substantial assumptions about the downstream man-
agement of TB that may limit the usefulness of any findings of such an analysis.
7 Expected impact
The expected impacts of the different policy options are differing levels of resource
use, largely because of staffing requirements to carry out the scaled-up interven-
tions, and a corresponding improvement in TB patient identification with down-
stream impact on TB care and ultimately reduced TB-related mortality and morbid-
ity. The use of more intensive screening interventions incurs more nurse time, and
improved sensitivity generates more diagnostic tests downstream with associated
costs but improved patient outcomes. A central assumption in predicting impact
is related to the causal pathway from diagnosis to appropriate treatment, and then
treatment to patient outcomes. In this analysis, common assumptions about treat-
ment outcomes are applied consistently to all interventions and are based on outputs
from the TIME epidemiological model. The major impact areas modelled include
deaths averted, numbers of patients screened for TB using the passive and WHO
approaches, the number of smear microscopy and Xpert diagnostic tests completed,
the number of patients initiated on first line and multi-drug resistant (MDR) regi-
mens, and reduction in the number of total person-years of untreated active disease.
Table 1 shows the expected impact of each of the interventions under consid-
eration on health system outcomes (in ’000s) over the 20-year period from 2015
to 2035 compared to the status quo3. Importantly, all interventions are expected
3 All results are reported as net present values in the year 2015 unless otherwise noted.
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Table 1 Intervention impact on health system outcomes 2015–2035 (in ‘000s).
Intervention* Untreated
active
disease
(person-
years)
No. patients
screened
(passive)
No. of
patients
screened
(cough
triage)
No. of
patients
screened
(WHO)
No. of
smear
micro-
scopies
completed
No. of
Xpert tests
completed
No. patients
initiated on
1st line
treatment
No. of
patients
initiated on
MDR
treatment
2 100% Xp −1,951 −404 73 −22 −21,409 21,008 −288 8
3 90% FU Xp - −1,132 −231 19 24 −57 −228 59 10
4 100% Xp &
90% FU Xp-
−3,134 −646 92 −7 −21,411 20,710 −228 19
5 100% HIV+
cough triage
−344 −65 766,088 −319,226 −5,658 −22,633 −219 1
6 90% PHC
cough triage
−1,233 −261 351,962 18 3,701 14,803 102 −4
7 100% HIV+ SS −6,384 −1,364 164 447,597 21,036 84,146 823 17
8 90% PHC SS −4,409 −942 −480,796 833,124 32,354 129,417 1,156 −14
9 100% Xp &
90% FU Xp-
& 90% PHC
cough triage
−4,274 −887 352,120 6 −21,285 39,095 −189 15
10 100% Xp & 90%
FU Xp- & 90%
PHC SS
−7,171 −1,510 −480,796 833,238 −20,517 181,649 385 3
∗Intervention results are presented incremental to status quo (intervention 1).
Xp = Xpert diagnostic test; FU = follow-up; PHC = primary health clinic; SS =WHO TB symptoms screening.
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to substantially reduce the number of person-years of untreated active disease – a
key indicator for reduction in TB transmission. Intervention 7 (100% screening of
all patients who are HIV+) is expected to result in more than 447 million patient
screening events using the structured WHO survey, with a resultant reduction in
number of patients passively screened, and an increase in diagnostic tests performed
and patients initiated on treatment. Intervention 10 (increased Xpert coverage and
follow-up, and symptoms screening of 90% of all PHC attendees) is expected to
yield the greatest reduction in untreated active disease, with more than 833 million
additional screens using the structured WHO survey and 182 million additional
Xpert diagnostic tests over the 20-year period.
8 Costs
The approach to costing in this analysis involved combining the output of the TIME
epidemiological model with costing parameters derived from local South African
data.
The cost of key elements within the care pathway were estimated using a micro-
costing approach. For example, costs of drug regimens were estimated by calculat-
ing total number of tablets/injections required over the course of treatment multi-
plied by their unit cost, and screening costs involved the unit cost of the test per
patient plus health professional time. Compared to the status quo scenario, the cost
impact of key elements of the management pathway for the period 2015–2035 are
detailed in Table 2, and are represented in South African Rand (ZAR) and Int$ using
Int$:ZAR exchange rate of 5.564 (OECD, 2018). The analysis applies a 3% annual
discount rate over the 20-year time horizon of the analysis with sensitivity analysis
using 0% and 5.04%, which is twice the expected near-term growth projection of
2.52%, motivated by the Ramsey rule4. Table 3 represents total cost impact under
different discount rates.
The Xpert diagnostic test is a driver of cost under most intervention scenarios.
Additional costs associated with Xpert as a result of implementing Intervention
10 (100% Xpert coverage, 90% follow-up of Xpert negative results and symptoms
screening in 90% of people attending primary health care clinics) are expected to be
in excess of $10.3 billion over the 20-year period, with an additional $92 million for
1st line and multi-drug resistant (MDR) TB treatment costs. Intervention 5 (cough
4 The International Monetary Fund average projected per capita GDP growth to 2023 for South Africa
(2.52%) (International Monetary Fund, 2018)
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Table 2 Cost of interventions by element of the treatment pathway 2015–2035 (in Int$ (millions) and South African Rand (ZAR, millions),
incremental to status quo).
Intervention Passive
screening
costs
Xpert test
costs
Smear
microscopy
costs
Patient
follow-up
costs*
Cough
triage costs
WHO
screening
costs
1st line
treatment
costs
MDR
treatment
costs
IPT
treatment
costs**
Total
(Int$)
Total
(ZAR)
2 100% Xp −$0.48 $1,195.08 −$410.61 −$4.58 $0.08 −$0.04 −$64.72 $121.36 −$0.04 $836 R4,652
3 90% FU Xp - −$0.28 −$13.08 −$1.10 $27.77 $0.02 $0.05 $13.99 $155.44 $0.05 $183 R1,017
4 100% Xp &
90% FU Xp-
−$0.78 $1,178.00 −$410.65 $29.44 $0.10 −$0.01 −$50.27 $295.99 −$0.01 $1,042 R5,797
5 100% HIV+
cough triage
−$0.09 −$1,251.27 −$105.47 −$0.12 $925.06 −$780.08 −$48.47 $19.43 −$0.09 −$1,241 −R6,906
6 90% PHC
cough triage
−$0.31 $844.87 $71.21 −$0.18 $423.59 $0.04 $23.83 −$49.10 $0.04 $1,314 R7,311
7 100% HIV+ SS −$1.63 $4,776.62 $402.62 −$1.86 $0.18 $1,071.58 $190.69 $290.59 $0.53 $6,729 R37,442
8 90% PHC SS −$1.11 $7,356.27 $620.06 −$0.65 −$591.83 $2,031.63 $264.36 −$184.71 $0.13 $9,494 R52,825
9 100% Xp &
90% FU Xp-
& 90% PHC
cough triage
−$1.06 $2,225.23 −$407.53 $29.18 $423.76 $0.02 −$40.74 $240.26 $0.02 $2,469 R13,738
10 100% Xp &
90% FU Xp- &
90% PHC SS
−$1.80 $10,310.88 −$388.51 $28.52 −$591.83 $2,031.89 $91.89 $88.46 $0.08 $11,570 R64,373
∗Cost of following up patients who have a negative Xpert result.
∗∗People living with HIV receiving isoniazid preventative therapy.
Xp = Xpert diagnostic test; FU = follow-up; PHC = primary health clinic; SS = TB symptoms screening.
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Table 3 Total cost of interventions by element of the treatment pathway 2015–2035 at
differing discount rates (in Int$, millions, incremental to status quo).
Intervention Total 0%
discount
rate
Total 3%
discount
rate
Total 5.04%
discount
rate
2 100% Xp $1,175 $836 $672
3 90% FU Xp - $257 $183 $147
4 100% Xp & 90% FU Xp- $1,464 $1,042 $838
5 100% HIV+ cough triage −$1,807 −$1,241 −$971
6 90% PHC cough triage $1,843 $1,314 $1,058
7 100% HIV+ SS $9,504 $6,729 $5,394
8 90% PHC SS $13,383 $9,494 $7,617
9 100% Xp & 90% FU Xp-
& 90% PHC cough triage
$3,468 $2,469 $1,987
10 100% Xp & 90% FU Xp-
& 90% PHC SS
$16,323 $11,570 $9,277
triage for 100% of HIV+ patients) is expected to result in savings in most elements
of care due to a reduction in TB cases over time.
9 Benefits
This case study adopts a benefits transfer approach as a literature search did not
identify literature of sufficient quality to estimate the value of statistical life (VSL)
or value of statistical life year (VSLY), or willingness to pay to reduce non-fatal
risks in South Africa directly (Robinson et al., 2019), (Robinson & Hammitt, 2018).
9.1 Value of mortality risk reduction
To calculate the value of mortality risk reduction, Equation (1) shows the approach
to calculating the values used in the benefits transfer, where the VSLtarget is the
estimated VSL in South Africa, VSLbase is the value in the originating country,
income is the GNI per capita adjusted for purchasing power parity, and elasticity
measures the change in the VSL associated with a change in income.
VSLtarget = VSLbase ∗ (Incometarget/Incomebase)elasticity. (1)
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Table 4 Estimated VSLs for South Africa ($Int, 2015).
Approach 1: GNI
per capita*160
(elasticity 1)
Approach 2: GNI
per capita*100
(elasticity 1)
Approach 3: GNI
per capita*160
(elasticity 1.5)
$2,054,400 $1,284,000 $981,652
The rationale and values used to estimate the VSL for the South African tar-
get population used in this case study are informed by Robinson et al. 2019, and
include three approaches for applying Equation (1). Approach 1 is based on the
ratio of GNI per capita to central VSL estimates commonly used in the United
States and Approach 2 uses VSL estimates commonly used across OECD coun-
tries. Both cases assume an income elasticity of 1.0. Approach 3 extrapolates from
the US value using an elasticity of 1.5, which has the effect of reducing the esti-
mated fraction of income devoted to spending on small risk reductions as income
decreases. All approaches adopt a per capita income for South Africa of $12,840
(2015, adjusted for ppp). Following the estimation of the VSL in South Africa for
the year 2015, the VSL was adjusted for expected changes in income over time.
The International Monetary Fund average projected annual GDP growth to 2023
for South Africa (2.52%) (International Monetary Fund, 2018) was assumed to rep-
resent a reasonable estimation of a constant annual expected change in per capita
income year to year and was used to estimate annual VSL growth to 2035, applying
the appropriate elasticities for each approach.
The term VSL is not an indication of a society’s or an individual’s valuation
of a human life; it represents how an individual values a change in his or her own
risk of mortality within a defined time frame. For example, a VSL of $981,652 in
Table 4 above is equivalent to individual willingness to pay of $98 for a 1-in-10,000
reduction in one’s own mortality risk; VSL is calculated by dividing willingness to
pay by the risk change.
The projected deaths avoided as a result of the different interventions over the
period 2015–2035 (undiscounted) are shown in Table 6. The sum valuation of the
mortality risk reduction was calculated using an income growth-adjusted VSL for
deaths averted in any calendar year and discounted to the year 2015. All interven-
tions are expected to avoid a substantial number of deaths relative to the status
quo, with the combination intervention 10 (100% Xpert coverage, 90% follow-up
of Xpert negative results and symptoms screening in 90% of people attending pri-
mary health care clinics) expected to yield the largest reduction in mortality with
over 73,000 deaths avoided over the 20-year period at an expected mortality risk
reduction monetized benefit of Int$79.9 billion.
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Table 5 Estimated VSLYs for South Africa for target population (Int$, 2015).
Approach 1: GNI
per capita*160
(elasticity 1)
Approach 2: GNI
per capita*100
(elasticity 1)
Approach 3: GNI
per capita*160
(elasticity 1.5)
$66,810 $41,756 $31,924
10 Value of morbidity risk reduction
By improving outcomes related to detection and treatment of TB, the interventions
are expected to result in reduced risk of morbidity (i.e. non-fatal health impacts) in
addition to reduced risk of death.
Using established disability weights from the literature for the relevant health
states (with and without active TB in combination with different HIV states)
(Salomon et al., 2012), the reduction in morbidity (represented by years lived in
disability (YLD) associated with each intervention incremental to the status quo
was calculated over the period 2015–2035.
To estimate the value of the morbidity risk reduction, the YLDs averted for each
intervention were multiplied by a constant VSLY. This approach relies on strong
assumptions including that (1) the VSLY is constant, (2) the VSLY as calculated
is equivalent to a DALY, and (3) the value per DALY is constant (Robinson &
Hammitt, 2018). Three values for the VSLY were estimated by extrapolating from
the approaches used to estimate VSL and dividing the respective VSL by 30.75
years, which is the mean expected number of years of life remaining for the average
adult in South Africa (Statistics South Africa, 2015) (World Health Organisation,
2015a) (Table 5).
Individual willingness to pay estimates are assumed to incorporate non-health
systems costs incurred by the individual, and so these costs are not added to the esti-
mates (Robinson & Hammitt, 2018). There is some uncertainty as to whether it is
appropriate to add averted third-party costs (e.g. those paid by household or family
members or an organization such as the government). An analysis of the economic
costs of TB in South Africa (Foster et al., 2015) found the mean guardian/carer costs
per diagnostic and treatment episode was US$114.10. Assuming this cost would
be incurred by third parties for all patients initiating first line or MDR treatment
under the different interventions, the impact of this third-party cost on the value of
morbidly reduction is incorporated in Table 6 for comparison. Inclusion of averted
third-party costs increases the net value associated with morbidity risk reduction for
interventions that result in a reduction in initiations of TB treatments over time (e.g.
increasing to 100% Xpert coverage), whereas inclusion of averted third-party costs
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Table 6 Total monetized benefit by mortality and years lived in disability incremental to status quo 2015–2035 (in Int$, ‘millions).
Intervention* Total deaths
averted
Monetized
benefit of
mortality risk
reduction
Total YLD
averted
Monetized
benefit of
morbidity risk
reduction
Monetized
benefit of
morbidity risk
reduction +
3rd-party costs)
Total monetized
benefit
(combined
mortality and
morbidity)*
2 100% Xp 17,913 $19,351 24,309 $854 $930 $20,205
3 90% FU Xp - 5,170 $5,569 9,189 $321 $303 $5,891
4 100% Xp & 90% FU Xp- 22,780 $24,597 34,203 $1,201 $1,257 $25,798
5 100% HIV+ cough triage 1,769 $1,832 5,047 $174 $233 $2,006
6 90% PHC cough triage 15,571 $16,827 14,815 $521 $494 $17,347
7 100% HIV+ SS 35,775 $38,490 52,771 $1,842 $1,615 $40,333
8 90% PHC SS 55,429 $59,912 53,039 $1,865 $1,557 $61,778
9 100% Xp & 90% FU Xp-
& 90% PHC cough triage
37,237 $40,213 48,181 $1,692 $1,739 $41,905
10 100% Xp & 90% FU Xp-
& 90% PHC SS
73,970 $79,903 83,701 $2,941 $2,835 $82,844
Monetized benefit calculated using estimated VSL in South African context of $ 981 652 (GNI per capita*160 (elasticity 1.5) (approach 3). Xp = Xpert
diagnostic test; FU = follow-up; PHC = primary health clinic; SS =WHO TB symptoms screening.
∗Excluding 3rd-party costs.
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reduces net value of interventions that increase the numbers initiating treatment
(e.g. cough triage in 90% patients visiting PHC), as additional treatment initiations
result in additional third-party costs. In this scenario, the inclusion of averted third-
party costs represents a small proportion of the benefit compared to the willingness
to pay estimates for morbidity risk reduction, with the mean increase in valuation
across the interventions ranging from 2.19% (when using Approach 1) to 3.94%
(when using Approach 3).
11 Net benefits and benefit cost ratios
The net benefits calculation subtracts total costs from total monetized benefits to
estimate net benefits as detailed in Table 7. All interventions are estimated to result
in positive net benefits compared to the status quo. Regardless of the approach
used to estimate the VSL, Intervention 10 (improved Xpert access and follow-up,
WHO symptoms screening in 90% of PHC patients) maximized net benefit over
the 20-year period, at between Int$137 billion (Approach 1) and Int$71.3 billion
(Approach 3). Intervention 5 (cough triage in all HIV+ patients) represented the
lowest net benefits, ranging from Int$5.1 billion (Approach 1) to Int$3.2 billion
(Approach 3).
The benefit-cost ratio (BCR) was calculated for each intervention by dividing
the expected outputs (which in this analysis was the monetized benefit of morbidity
and mortality risk reductions) by the respective implementation costs, where the
value of the BCR indicates the expected monetary return for each dollar invested.
Intervention 5 was estimated to be cost saving to the health system (i.e. had nega-
tive input costs) and so the BCR cannot be calculated but is represented in the table
as greater than 100 to give an indication of relative favourable returns. Interven-
tion 10, which was estimated to have the greatest net benefits of all the interven-
tions, has a relatively low estimated BCR, reflecting the large costs associated with
implementation.
12 Distribution of effects
Incidence of TB is heavily influenced by income and socioeconomic status. Despite
significant reductions in the rate of poverty5 from 1996, the poverty rate in South
Africa has increased to 18.9% in 2015 from 16.9% in 2008. As TB is both a cause
5 Poverty defined as below $1.90 per day (ppp).
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Table 7 Net benefit by intervention, incremental to status quo 2015–2035 (in Int$ millions and ZAR millions).
Intervention Net benefit1
(Int$)
Net benefit1
(ZAR)
Net benefit2
(Int$)
Net benefit2
(ZAR)
Net benefit3
(Int$)
Net benefit3
(ZAR)
Benefit-cost
ratio4
2 100% Xp $35,466 R197,334 $21,853 R121,589 $19,369 R107,770 24
3 90% FU Xp - $10,450 R58,144 $6,463 R35,958 $5,708 R31,757 32
4 100% Xp & 90% FU Xp- $45,345 R252,300 $27,950 R155,514 $24,756 R137,741 25
5 100% HIV+ cough triage $5,086 R28,299 $3,644 R20,276 $3,247 R18,067 >100
6 90% PHC cough triage $29,838 R166,016 $18,156 R101,019 $16,033 R89,210 13
7 100% HIV+ SS $66,217 R368,430 $38,862 R216,228 $33,603 R186,969 6
8 90% PHC SS $101,395 R564,164 $59,812 R332,793 $52,284 R290,907 7
9 100% Xp & 90% FU Xp-
& 90% PHC cough triage
$72,861 R405,398 $44,612 R248,222 $39,436 R219,420 17
10 100% Xp & 90% FU Xp-
& 90% PHC SS
$137,287 R763,867 $81,466 R453,277 $71,274 R396,570 7
1Monetized benefit calculated using estimated VSL in South African context of $2,054,400 (GNI per capita*160 (elasticity 1.0) (Approach 1).
2Monetized benefit calculated using estimated VSL in South African context of $1,284,000 (GNI per capita*100 (elasticity 1.0) (Approach 2).
3Monetized benefit calculated using estimated VSL in South African context of $981,652 (GNI per capita*160 (elasticity 1.5) Approach 3).
4Benefit-cost ratio calculated using outputs VSL Approach 3.
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and effect of poverty, the distribution of the social benefits and costs associated with
the TB control interventions across the South African population is highly relevant
to the policy recommendation (Robinson et al., 2018).
Even though TB care in South Africa is largely free at the point of use, patients
experience direct and indirect costs associated with the disease and in accessing
TB diagnosis and treatment. An extended cost-effectiveness analysis that utilized
the same epidemiological model (TIME) as this case study estimated the impact of
expanded TB services on households in South Africa and India and showed sub-
stantial variation in the impact of suffering from TB and accessing TB care across
income quintiles (Verguet et al., 2016). The study found that in the South African
base case scenario, 1.1 to 1.2 million households would experience catastrophic
costs related to TB over the period 2015–2030, with 80% of catastrophic costs
experienced in the bottom quintile, and zero households in the top quintile expe-
riencing catastrophic costs. Expanded access to TB services in South Africa was
estimated to reduce TB-related catastrophic costs by 5–20%, with the majority of
benefits accruing to poorest households.
All interventions within this case study reduce the amount of untreated active
TB and avert significant morbidity and mortality. This case study was unable to
make accurate quantitative estimations of the distributional impacts of the different
interventions as although the socioeconomic status of patients passively screened
for TB is known, it is uncertain precisely how the benefits of more intensified case
finding and screening will be distributed. However, it is expected that the inter-
vention effects will mainly be experienced by impoverished households and that
interventions with larger reductions in TB-associated morbidity and mortality will
have a greater impact on households in lower-income quintiles. As TB interventions
in South Africa are largely delivered in the public sector, the cost of the interven-
tions falls on government revenue through a broadly progressive taxation system,
indicating that the health system costs of the interventions are more likely to fall on
households in higher-income quintiles.
13 Discussion
This case study aimed to demonstrate the methodological specifications for the
conduct of BCA and was applied to an existing CEA of 10 interventions to improve
access and diagnosis of TB in the South African setting.
The CEA results found that Intervention 5 (cough triage in 100% of HIV+
patients) is expected to result in net health service savings and generate positive
health outcomes, and would likely receive a positive policy recommendation even
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under scenarios where the cost-effectiveness threshold (CET) is either extremely
low or unknown. Interventions 3, 4, 6, 7 and 8 are either strongly or weakly domi-
nated, indicating that for any given cost-effectiveness threshold, an alternative mix
of interventions exist that represents a more favourable use of resources6. Interven-
tion 10 (100% Xpert coverage, 90% follow-up of Xpert negatives and WHO symp-
toms screen in 90% of all PHC patients) is expected to have the highest incremental
cost-effectiveness ratio (ICER) and represents a potentially viable policy option in
addition to Intervention 5 and Intervention 9 (100% Xpert coverage and follow-up
of 90% of patients with a negative Xpert result) depending on the cost-effectiveness
threshold used in the South African setting to guide health system investments7.
Further interpretation of the CEA results will be discussed in the report of the CEA
analysis (Bozzani et al., 2019).
Under the BCA framework, Intervention 5 (triaging all people who are HIV+
who have a cough for TB management rather than applying the WHO screening
survey before referral) represents the lowest net benefit but most favourable BCR.
This is because while the health impacts are relatively small (averting approxi-
mately 1,500 deaths and 5,000 years lived in disability), this intervention is likely
to achieve substantial savings (Int$1.24 billion) compared to status quo over time
as a result of reduced staff time and diagnostic tests. Intervention 10 has the high-
est net benefit under all approaches to VSL calculation, but a relatively low BCR
given the high implementation costs. Applying a VSL of between Int$0.98–Int$2.1
million to decreased mortality risk reduced the relative importance of small changes
in input costs between interventions, resulting in the intervention with the greatest
health impact yielding the greatest net benefit therefore under this analysis, Inter-
vention 10 represents the welfare maximizing policy option.
The BCA applied estimated willingness to pay to monetize health benefits and
did not separately represent economy-wide impacts such as economic growth or
unemployment rate. The strong links between TB and poverty suggests that there
may be economic benefits of reduced risk of TB-associated morbidity and mortality
in addition to the monetized benefits addressed. Further research on the relationship
between variables such as economic growth and TB and other priority conditions
would provide useful evidence to extend this analysis.
Contrasting the results utilizing the CEA and BCA frameworks highlight the
differing theoretical underpinnings of the approaches. The CEA provides a series
of ICERs estimating incremental health system costs as a ratio to a measure of
6 See Chapter 4, pp. 98–102, (Drummond et al., 2015).
7 South Africa does not have an established cost-effectiveness threshold that is routinely used for
interpretation of CEA results, although some estimates using local and international data are available
that may inform threshold development (Meyer-Rath et al., 2017), (Woods et al., 2016).
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health benefit, in this case producing a cost per DALY averted. The BCA provides
net benefits as a function of health system and caregiver costs and monetized val-
uations for mortality and morbidity risk reduction. The BCA also provides BCR
estimates, which in this analysis is conceptually similar to the calculation of a cost-
effectiveness ratio in CEA where BCR represents total outputs and inputs while
an ICER represents incremental costs and effects. Incremental analysis identifies
the costs and effects of an intervention relative to the next most effective (or least
costly) intervention in the analysis and so is able to exclude interventions that are
more costly and less effective than other interventions (or combinations of inter-
ventions), thereby providing an indication of the opportunity cost of the alterna-
tive options. Although there is no fundamental methodological barrier to using an
incremental approach in calculation of BCR, the BCR method commonly repre-
sents total inputs and outputs relative to a common comparator, which in an anal-
ysis involving multiple mutually exclusive interventions may provide an inaccu-
rate indication of opportunity cost and should be interpreted with caution in this
case study.
The CEA and BCA approaches in this case study reflect a judgement on
whether social values embedded in economic evaluation ought to reflect those
implied by the outcome of policy processes (such as government setting budgets for
health care) or a notion of welfare founded on individual preferences or an explicit
welfare function (Claxton, 2018). A limitation of applying the results of the BCA
in a policy recommendation is the extent to which a monetized value of individual
preferences for changes in one’s own risks is valid in determining health policy in
South Africa given historical and persistent levels of inequity and access to care.
If so, a further limitation is whether the uncertainty resulting from the benefits
transfer approach enables an acceptable estimation of welfare in the South African
context. However, utilizing CEA results also suffers from comparable limitations
in the calculation and valuation of health effects and uncertainty in the extent to
which the objective function to maximize health should be weighed against other
values important to the South African population.
A key consideration for interpretation of both the BCA and CEA approaches is
health system affordability. Simplistic decision rules to implement policies based
on analytical outputs (be that CEA or BCA or another form of analysis) that are
not linked to available funding has the potential to result in net population loss of
welfare (under a BCA framework) or health (under a CEA framework) if more effi-
cient interventions are pushed out to fund new investments. In the South African
context, completion of ongoing work to accurately estimate the marginal productiv-
ity of the public health system will assist in the interpretation of CEA results, while
local estimations of willingness to pay for mortality and morbidity risk reductions
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in addition to consideration of the appropriate interpretation of BCA results in the
context of the objectives of the South African health system is required. BCA poten-
tially offers further analytical insight for interventions with substantial non-health
and non-pecuniary benefits and costs; however, approaches to co-financing inter-
ventions with multi-sectoral impacts also demonstrates the utility of CEA in this
policy context (Remme et al., 2017).
The results of this case study may contribute to further understanding of the
nature and relationship of the costs and benefits of the different TB control inter-
ventions and the appropriate analytical technique to demonstrate value relative to
other health system priorities. Ultimately, the validity of the differing approaches
rests on the requirements, understanding, and informational needs of the intended
decision maker, and the realities of local perspective, and context.
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